# Metabolomics Market Size, Share, Growth, and Trends Analysis - Global Forecast to 2036 | Market to Reach USD 8.74 Billion as Clinical Diagnostics and AI Drive 9.5% CAGR

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/metabolomics-market-size-share-growth-and-trends-analysis-global-forecast-to-2036-market-t/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

*Boost ROI through clinical diagnostics, targeted assays, AI bioinformatics, standardized kits, outsourced services, and end-to-end workflow partnerships.*

Dublin, Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.researchandmarkets.com/reports/6290697/metabolomics-market-size-share-trends?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=76vsp2&amp;utm_campaign=2404373+-+Metabolomics+Market+Size%2c+Share%2c+Growth%2c+and+Trends+Analysis+-+Global+Forecast+to+2036+%7c+Market+to+Reach+USD+8.74+Billion+as+Clinical+Diagnostics+and+AI+Drive+9.5%25+CAGR&amp;utm_exec=clshmsai" rel="nofollow">"Metabolomics Market Size, Share, and Trends Analysis - Global Forecast to 2036"</a> has been added to **ResearchAndMarkets.com's** offering.

The global metabolomics market was valued at USD 3.21 billion in 2025 and is estimated to reach USD 3.52 billion in 2026. The market is projected to grow to USD 8.74 billion by 2036, registering a CAGR of 9.5% during the forecast period 2026-2036. Growth is being supported by rising demand for biomarker discovery, drug development, population-scale studies, clinical testing, multiomics research, and advanced analytical technologies.

The report assesses instruments, consumables & kits, software & bioinformatics, and services used across metabolomics and lipidomics workflows. Technologies covered include LC-MS, GC-MS, CE-MS, mass spectrometry imaging, and NMR systems, along with targeted kits, standards, reagents, columns, data processing platforms, compound identification tools, pathway mapping software, and contract research services.

**Market Growth Drivers and Opportunities**

Biomarker discovery and drug development remain the primary growth drivers for the metabolomics market. Pharmaceutical and biotechnology companies increasingly use metabolite profiles to identify therapeutic targets, evaluate mechanism of action, monitor pharmacodynamic effects, assess safety, and stratify clinical trial participants. Population cohorts connecting metabolic data with genetic information and electronic health records are also creating demand for consistent, high-volume sample analysis.

In November 2025, Nightingale Health completed the release of NMR metabolic profiles for all 500,000 UK Biobank participants. The company has also delivered blood analysis results to more than 200,000 people in Finland through occupational health checks with Terveystalo. In February 2026, the New York State Department of Health granted Nightingale Health a clinical laboratory permit. Metabolon reports more than 15,000 completed projects and over 4,000 supported publications during 25 years of operations.

Technology innovation is strengthening market expansion. At the June 2026 ASMS conference, Thermo Fisher Scientific, Waters, Bruker, and Shimadzu introduced high-resolution, ion mobility, or triple quadrupole systems, while SCIEX expanded its ZenoTOF 8600 platform. These developments support higher sensitivity, faster scanning, and improved isomer separation.

Clinical translation represents a major opportunity, particularly in preventive health, disease risk assessment, and treatment monitoring. Waters' February 2026 combination with BD's Biosciences and Diagnostic Solutions businesses established an Advanced Diagnostics division focused on regulated clinical testing workflows, including multiplex LC-MS testing. Additional opportunities include standardized quantitative kits, AI-assisted metabolite identification, nutrition research, microbiome studies, agriculture, and bio-manufacturing.

Market adoption is constrained by the capital and operating costs associated with high-resolution mass spectrometers and high-field NMR systems. Skills shortages across sample preparation, chromatography, instrument operation, data processing, and interpretation also affect study capacity. Other challenges include incomplete metabolome coverage, unidentified signals in untargeted studies, and limited standardization across methods, reference materials, and reporting formats.

**Segment Highlights**

-   **Offering:** Instruments are expected to hold the largest market share in 2026, led by mass spectrometry systems and LC-MS platforms. Software & bioinformatics is projected to record the highest CAGR as AI analytics, metabolite identification, and multiomics integration become more widely adopted.
-   **Approach:** Untargeted metabolomics is expected to account for the larger share in 2026 due to its role in biomarker and pathway discovery. Targeted metabolomics is forecast to grow faster, supported by standardized kits, accurate quantification, population studies, and clinical testing.
-   **Application:** Biomarker discovery is projected to lead the market in 2026. Clinical diagnostics & precision medicine is expected to achieve the highest CAGR as metabolic testing expands into preventive care and regulated laboratory workflows.
-   **Indication:** Oncology is expected to hold the largest share, while cardiovascular & metabolic disorders are projected to grow at the highest CAGR. Inborn errors of metabolism remain an established clinical application, particularly in newborn screening.
-   **End user:** Academic & research institutes are expected to lead in 2026. Hospitals & diagnostic laboratories are forecast to record the fastest growth as mass spectrometry-based testing and metabolic panels enter broader clinical use.

**Regional Outlook**

North America is expected to lead the global metabolomics market in 2026, supported by research funding, academic core facilities, pharmaceutical and biotechnology activity, clinical mass spectrometry adoption, and the presence of major industry participants. Europe is projected to retain a significant share, driven by UK Biobank, clinical metabolic testing in Finland, research cohorts in Italy and Denmark, and established companies in Germany and Austria.

Asia-Pacific is forecast to register the highest CAGR during 2026-2036 due to expanding research investment, population health initiatives, and pharmaceutical sector growth. China is expected to hold the largest regional share, while Japan, South Korea, India, Australia, and Singapore offer strong growth potential. Thermo Fisher Scientific's collaboration with Precision Health Research, Singapore, on the PRECISE-SG100K study illustrates the region's expanding population-scale research activity. Latin America and the Middle East & Africa are also generating opportunities through agricultural research and national precision medicine initiatives.

**Competitive Landscape**

Leading metabolomics market participants include Thermo Fisher Scientific Inc., Agilent Technologies, Inc., Waters Corporation, Bruker Corporation, Danaher Corporation through SCIEX, Shimadzu Corporation, JEOL Ltd., LECO Corporation, Metabolon, Inc., Nightingale Health Plc, and Human Metabolome Technologies, Inc.

Competition centers on analytical performance, workflow integration, standardized kits, AI-enabled software, and service capacity. Strategic consolidation is accelerating as instrument manufacturers expand beyond hardware. Notable developments include Bruker's acquisition of biocrates in June 2025 following earlier transactions involving PreOmics and Biognosys, Waters' combination with BD's biosciences and diagnostics businesses, and Thermo Fisher Scientific's PRECISE-SG100K collaboration.

The report provides market forecasts, segment analysis, regional assessments, competitive benchmarking, company profiles, market share analysis, and evaluations of growth strategies. It supports product planning, partnership development, acquisition screening, service expansion, investment assessment, and market entry decisions across the global metabolomics industry.

**Key Topics Covered:**  
  
**1\. Introduction**  
1.1. Market Definition  
1.2. Market Ecosystem  
1.3. Currency and Limitations  
1.3.1. Currency  
1.3.2. Limitations  
1.4. Key Stakeholders  
  
**2\. Research Methodology**  
2.1. Research Approach  
2.2. Data Collection & Validation Process  
2.2.1. Secondary Research  
2.2.2. Primary Research & Validation  
2.2.2.1. Primary Interviews with Industry Experts  
2.2.2.2. Country-/Region-Level Analysis  
2.3. Market Estimation  
2.3.1. Bottom-Up Approach  
2.3.2. Top-Down Approach  
2.3.3. Forecast Methodology  
2.4. Data Triangulation  
2.5. Assumptions  
  
**3\. Executive Summary**  
  
**4\. Market Overview**  
4.1. Introduction  
4.2. Market Dynamics  
4.2.1. Drivers  
4.2.1.1. Increasing Use of Metabolomics in Biomarker Discovery and Drug Development  
4.2.1.2. Growth of Population-Scale Metabolomic Studies  
4.2.1.3. Advances in High-Resolution Mass Spectrometry and NMR Technologies  
4.2.1.4. Growing Adoption of Multiomics Approaches  
4.2.2. Restraints  
4.2.2.1. High Cost of Advanced Instruments  
4.2.2.2. Shortage of Skilled Personnel and Complex Workflows  
4.2.3. Opportunities  
4.2.3.1. Clinical Translation and Preventive Healthcare  
4.2.3.2. Standardized Quantitative Kits and Targeted Assays  
4.2.3.3. AI-Enabled Software for Metabolite Identification and Interpretation  
4.2.3.4. Expansion of Metabolomics in Nutrition, Microbiome, and Bio-Manufacturing  
4.2.4. Challenges  
4.2.4.1. Metabolite Identification and Chemical Diversity  
4.2.4.2. Lack of Standardization and Data Comparability  
4.2.5. Trends  
4.2.5.1. Ion Mobility and High-Resolution Platforms for Isomer Separation  
4.2.5.2. Consolidation and Expansion of Instrument Companies into Workflows  
4.2.5.3. Large Metabolomic Datasets and Data-Driven Research  
4.3. Technology Landscape  
4.3.1. Liquid Chromatography-Mass Spectrometry (LC-MS)  
4.3.2. Gas Chromatography-Mass Spectrometry (GC-MS)  
4.3.3. Capillary Electrophoresis-Mass Spectrometry (CE-MS)  
4.3.4. NMR Spectroscopy  
4.3.5. Ion Mobility Spectrometry  
4.3.6. Mass Spectrometry Imaging and Spatial Metabolomics  
4.3.7. AI and Machine Learning in Metabolite Identification  
4.4. Mass Spectrometry vs. NMR in Metabolomics: Comparative Analysis  
4.5. Metabolomics Ecosystem  
4.5.1. Instrument Manufacturers  
4.5.2. Kit, Reagent, and Standards Providers  
4.5.3. Software and Database Providers  
4.5.4. Contract Metabolomics Service Providers  
4.5.5. Academic Core Facilities and Population Studies  
4.5.6. Pharmaceutical, Clinical, and Industrial End Users  
4.6. Value Chain Analysis  
4.6.1. Study Design and Sample Collection  
4.6.2. Sample Preparation  
4.6.3. Separation and Detection  
4.6.4. Data Processing and Metabolite Identification  
4.6.5. Statistical and Biological Interpretation  
4.7. Regulatory Landscape  
4.7.1. Clinical Laboratory Regulations (CLIA, EU IVDR)  
4.7.2. Newborn Screening and Clinical Mass Spectrometry  
4.7.3. Data Standards and Reporting Initiatives  
4.8. Porter's Five Forces Analysis  
4.9. Population-Scale Metabolomics Projects Analysis  
4.10. Pricing Analysis  
  
**5\. Metabolomics Market, by Offering**  
5.1. Introduction  
5.2. Instruments  
5.2.1. Mass Spectrometry Systems  
5.2.1.1. LC-MS  
5.2.1.2. GC-MS  
5.2.1.3. CE-MS  
5.2.1.4. Mass Spectrometry Imaging  
5.2.2. NMR Spectroscopy Systems  
5.2.3. Chromatography Systems  
5.2.4. Other Instruments  
5.3. Consumables & Kits  
5.3.1. Targeted Metabolomics Kits  
5.3.2. Standards & Reagents  
5.3.3. Columns & Other Consumables  
5.4. Software & Bioinformatics  
5.5. Services  
  
**6\. Metabolomics Market, by Approach**  
6.1. Introduction  
6.2. Untargeted Metabolomics  
6.3. Targeted Metabolomics  
  
**7\. Metabolomics Market, by Application**  
7.1. Introduction  
7.2. Biomarker Discovery  
7.3. Drug Discovery & Development  
7.4. Clinical Diagnostics & Precision Medicine  
7.5. Toxicology & Environmental Testing  
7.6. Nutrition & Food Testing  
7.7. Agriculture & Plant Research  
7.8. Other Applications  
  
**8\. Metabolomics Market, by Indication**  
8.1. Introduction  
8.2. Oncology  
8.3. Cardiovascular & Metabolic Disorders  
8.4. Neurological Disorders  
8.5. Inborn Errors of Metabolism  
8.6. Other Indications  
  
**9\. Metabolomics Market, by End User**  
9.1. Introduction  
9.2. Academic & Research Institutes  
9.3. Pharmaceutical & Biotechnology Companies  
9.4. Contract Research Organizations & Service Providers  
9.5. Hospitals & Diagnostic Laboratories  
9.6. Food, Nutrition & Agriculture Companies  
  
**10\. Metabolomics Market, by Geography**  
10.1. Introduction  
10.2. North America  
10.2.1. U.S.  
10.2.2. Canada  
10.3. Europe  
10.3.1. Germany  
10.3.2. U.K.  
10.3.3. France  
10.3.4. Italy  
10.3.5. Spain  
10.3.6. Netherlands  
10.3.7. Austria  
10.3.8. Finland  
10.3.9. Denmark  
10.3.10. Rest of Europe  
10.4. Asia-Pacific  
10.4.1. China  
10.4.2. Japan  
10.4.3. South Korea  
10.4.4. India  
10.4.5. Australia  
10.4.6. Singapore  
10.4.7. Rest of Asia-Pacific  
10.5. Latin America  
10.5.1. Brazil  
10.5.2. Mexico  
10.5.3. Rest of Latin America  
10.6. Middle East & Africa  
10.6.1. Saudi Arabia  
10.6.2. UAE  
10.6.3. Qatar  
10.6.4. Rest of Middle East & Africa  
  
**11\. Competitive Landscape**  
11.1. Overview  
11.2. Key Growth Strategies  
11.3. Competitive Benchmarking  
11.4. Competitive Dashboard  
11.4.1. Market Leaders  
11.4.2. Market Differentiators  
11.4.3. Vanguards  
11.4.4. Emerging Players  
11.5. Market Share/Rank Analysis, by Key Player (2025)  
  
**12\. Company Profiles**  
12.1. Thermo Fisher Scientific Inc.  
12.2. Agilent Technologies, Inc.  
12.3. Waters Corporation  
12.4. Bruker Corporation  
12.5. Danaher Corporation (SCIEX)  
12.6. Shimadzu Corporation  
12.7. JEOL Ltd.  
12.8. LECO Corporation  
12.9. Metabolon, Inc.  
12.10. Nightingale Health Plc  
12.11. Human Metabolome Technologies, Inc.  
  
**13\. Appendix**  
13.1. Related Reports  
13.2. Customization Options  
  
**List of Tables \[300\]**  
**List of Figures \[44\]**  
  
For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6290697/metabolomics-market-size-share-trends?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=76vsp2&amp;utm_campaign=2404373+-+Metabolomics+Market+Size%2c+Share%2c+Growth%2c+and+Trends+Analysis+-+Global+Forecast+to+2036+%7c+Market+to+Reach+USD+8.74+Billion+as+Clinical+Diagnostics+and+AI+Drive+9.5%25+CAGR&amp;utm_exec=clshmsai" rel="nofollow">https://www.researchandmarkets.com/r/7943a0</a>

**About ResearchAndMarkets.com**  
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood,Senior Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900 

  
![](https://ml.globenewswire.com/media/MmFhZDA0NGUtMDYwMS00YzJlLTg5YmMtZTk2Y2EyYWRmNjgwLTEwMjY3MzctMjAyNi0xMS0xNi1lbg==/tiny/Research-and-Markets.png)

## Related

- [Clinical Trial Management Systems (CTMS) - Global Strategic Business Report 2026: Capitalize on 17.5% CAGR to $7 Billion by 2032; Benchmark Oracle, Veeva Systems, Medidata Solutions and ArisGlobal](https://healthcarenews.io/news/clinical-trial-management-systems-ctms-global-strategic-business-report-2026-capitalize-on.md)
- [Clinical Trial Imaging - Global Strategic Business Report 2026: Capitalize on the $1.3 Billion Market as Bioclinica, Icon PLC, Parexel, and Ixico Disrupt AI-Driven Trials by 2032](https://healthcarenews.io/news/clinical-trial-imaging-global-strategic-business-report-2026-capitalize-on-the-1-3-billion.md)
- [E-Clinical Trial Technologies - Global Strategic Business Report 2026: Capitalize on 16.6% CAGR to US$32.8 Billion by 2032 as Oracle, Medidata, BioClinica and PAREXEL Disrupt Digital Trials](https://healthcarenews.io/news/e-clinical-trial-technologies-global-strategic-business-report-2026-capitalize-on-16-6-cag.md)
- [Genomic Clinical Decision Support Market Size, Share, Trends, and Forecast, 2026-2036 | AI, EHR Integration, and Pharmacogenomics Drive 13.8% CAGR to USD 5.18 Billion by 2036](https://healthcarenews.io/news/genomic-clinical-decision-support-market-size-share-trends-and-forecast-2026-2036-ai-ehr-i.md)
